UNSPSC 51332200: Antipsychotic benzazepines

Antipsychotic drugs made from compounds with benzene fused to azepines.

UNSPSC 51332200 Antipsychotic benzazepines is a Class code that in practice encompasses a much broader range of pharmaceutical and over-the-counter products than its nominal scope suggests. State and local governments purchasing under this code are actually procuring generic multi-source pharmaceuticals, OTC products, naloxone and drug deactivation systems, and related prescription fulfillment services. Recent solicitations show county health departments, state HHS agencies, and cooperative purchasing alliances (regional multi-jurisdictional procurement vehicles) as the primary issuing bodies. Work being solicited includes direct supply agreements with manufacturers and wholesalers for pharmaceutical distribution to public health facilities, establishment of direct-to-manufacturer prescription programs to improve cost management and fulfillment efficiency, and procurement of specific quantities of naloxone and drug deactivation systems for community health initiatives.

Recent activity spans Florida, Texas, and Minnesota. Seminole County, Florida released IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023, for quarterly delivery to the Seminole County Community Health Building. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, as a preliminary market intelligence solicitation exploring vendor capabilities for direct-to-manufacturer prescription contracting outside traditional pharmacy benefit manager and group purchasing organization channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 on January 20, 2026, with a March 26, 2026 response deadline, establishing multiple contracts for generic pharmaceuticals and OTC products distributed across participating state and local government facilities in Minnesota, Oregon, and other alliance members through three authorized wholesalers. MMCAP's RFP weights price competitiveness at 75 percent and requires vendors to maintain commercial general liability insurance of $5,000,000 per occurrence and comply with current Good Manufacturing Practices and the Drug Supply Chain Security Act.